Anticonvulsant Effects of Cannabidiol in Dravet Syndrome

Comment

Mohamad Koubeissi. Epilepsy Curr. 2017 Sep-Oct.

. 2017 Sep-Oct;17(5):281-282.

doi: 10.5698/1535-7597.17.5.281.

No abstract available

Comment on

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Devinsky O, et al. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. N Engl J Med. 2017. PMID: 28538134 Clinical Trial.

1. Porter BE, Jacobson C.. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013; 29: 574– 577. - PMC - PubMed
1. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR.. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016; 15: 270– 278. - PubMed
1. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. . Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017; 376: 2011– 2020. - PubMed
1. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutiérrez SO, van der Stelt M, López-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C, Lutz B.. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003; 302: 84– 88. - PubMed
1. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ.. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003; 30: 129– 37. - PubMed